Understanding why some head and neck cancer patients do not respond to immunotherapy
Dissecting temporal and spatial dynamics of immunotherapy resistance
This study is looking into why some patients with recurrent or metastatic head and neck cancer don’t respond well to certain immune treatments, and it aims to find ways to improve these treatments by understanding how the cancer and immune cells change during therapy.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts Eye and Ear Infirmary NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11060027 on NIH RePORTER |
What this research studies
This research investigates the reasons behind the limited effectiveness of immune checkpoint inhibitors (ICIs) in treating recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). By analyzing the tumor immune microenvironment and how it changes over time and space during treatment, the study aims to identify specific tumor and immune cell characteristics that contribute to resistance against ICIs. Innovative techniques like single-cell sequencing and imaging will be used to track these changes and develop better predictive biomarkers for treatment response. Ultimately, the goal is to enhance cancer care by identifying new therapeutic targets and improving patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with recurrent or metastatic head and neck squamous cell carcinoma who are receiving immune checkpoint inhibitor therapy.
Not a fit: Patients with early-stage head and neck cancer or those not receiving immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy treatments for head and neck cancer patients, improving their chances of response and survival.
How similar studies have performed: Previous research has shown promise in understanding tumor-immune interactions in other cancers, suggesting that this approach may yield valuable insights in head and neck cancer as well.
Where this research is happening
Boston, United States
- Massachusetts Eye and Ear Infirmary — Boston, United States (Active)
Researchers
- Principal investigator: Faden, Daniel — Massachusetts Eye and Ear Infirmary
- Study coordinator: Faden, Daniel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.